BioBridgeX
Log inCompare quotes
Discovery

Medicinal & Synthetic Chemistry CROs

Free for buyersNeutral marketplace
Quick answer

Medicinal and synthetic chemistry is the design and hands-on synthesis of drug-like molecules: custom synthesis, route scouting, analog libraries, research-scale scale-up, and analytical characterization. You need it across discovery, from making screening hits to driving the design-make-test-analyze cycles of lead optimization. On BioBridgeX, buyers source and compare qualified med chem CROs and contract directly with their chosen supplier, free for buyers.

Medicinal & Synthetic Chemistry CROs on BioBridgeX

We are qualifying and publishing Medicinal & Synthetic Chemistry CROs now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What is medicinal and synthetic chemistry, and when do you need it?

Medicinal chemistry is the discipline that turns a molecular idea into a real, testable compound and then improves it. Synthetic chemistry is the bench work that actually makes those molecules. In practice the two travel together: a chemist designs an analog to fix a liability (poor solubility, a metabolic soft spot, weak selectivity), figures out a route to make it, runs the synthesis, purifies it, and confirms what came out of the flask is what was drawn on the whiteboard. A med chem CRO sells that loop, either as discrete custom synthesis or as an embedded team running it for your program week after week.

You reach for this service at several points in discovery, not just one. Early on you need building blocks, intermediates, and reference standards to support assay development and screening. Once a screen produces hits, you need resynthesis to confirm the structure and the activity are real and not an artifact of a degraded or mis-registered library sample. Through hit-to-lead and lead optimization, medicinal and synthetic chemistry is the engine: designing the next round of analogs against the structure-activity relationship (SAR) you are building, making twenty or fifty compounds, feeding them into potency, selectivity, and ADME assays, and using those results to design the next round. The same group also delivers chiral resolution, late-stage functionalization, isotope labeling, and the milligram-to-gram scale-up that in vivo PK and early tox studies consume.

This is overwhelmingly a small-molecule discipline, including the harder corners of it: macrocycles, PROTACs and other targeted degraders, covalent inhibitors, peptidomimetics, and fragment elaboration. It sits firmly in discovery, which means almost all of it is research-grade work under good scientific documentation rather than GLP or GMP. The regulated synthesis of an API for the clinic is a different service and a different stage (CMC and manufacturing), and the chemistry skills overlap but the quality system and the cost do not.

What does a medicinal and synthetic chemistry CRO actually do?

At the simplest level a med chem CRO is a contract synthesis lab: you send a structure, they quote a price and a timeline, and they ship you the compound with an analytical data package (LC-MS, NMR, and a purity figure, typically by HPLC). That covers one-off custom synthesis, building blocks, intermediates, reference standards, and impurity or metabolite standards. But the more valuable engagements are design-inclusive, where the CRO's chemists contribute to which molecules to make next, not just how to make a structure you already drew.

The work most buyers are really sourcing falls into a handful of buckets. Library and analog synthesis: making focused sets of compounds around a chemical series to map SAR. Route scouting and process-aware synthesis: finding a synthetic route that is reliable, scalable, and free of problematic reagents, which matters the moment you need to make more than a few milligrams. Scale-up of research quantities: taking a route from milligrams to grams (and sometimes tens of grams) to feed in vivo efficacy, PK, and dose-range-finding studies. Separations and characterization: chiral and achiral purification, structure elucidation by NMR, and analytical method development. And specialist chemistry that not every shop has: organometallic and transition-metal catalysis, photoredox, fluorination, stable-isotope labeling for DMPK, and the synthesis of bifunctional degraders.

How the relationship is structured matters as much as the menu. FTE (full-time-equivalent) staffing buys you a dedicated chemist or team for a fixed monthly rate, which suits an active lead-optimization program with continuous demand and rewards continuity and accumulated context. Fee-for-service (per-compound or per-project) suits well-defined, finite synthesis. Many programs blend the two. The other distinction worth nailing down is whether the engagement includes design input or is pure synthesis-to-spec, because the price, the talent you need, and the IP terms all change with the answer.

How do you choose a medicinal and synthetic chemistry CRO?

The headline rate per compound is the least informative number in the quote. What actually separates a strong med chem partner from a frustrating one is chemistry capability against your specific molecules, the turnaround on a design-make-test cycle, and clean, honest data with IP terms that leave you owning what you paid to discover. Score two or three candidates against the same written scope and the same example structures, including a deliberately hard one, rather than collecting quotes that measure different things.

Use the checklist below as the diligence frame, and ask for relevant examples in your chemical series, not a generic capabilities deck.

  • Quality and documentation status: discovery med chem is research-grade, not GLP, so confirm the analytical package you get with every compound (LC-MS, NMR, HPLC purity threshold), electronic-notebook practice, and sample chain-of-custody. Ask what purity bar they certify to and how they handle a batch that misses it.
  • Chemistry capability and modality fit: match the lab to your molecules. A shop that is excellent at routine analog synthesis may be a beginner at macrocycles, PROTACs, covalent warheads, complex heterocycles, or transition-metal and photoredox chemistry. Ask which hard reactions they run in-house versus subcontract, and to see comparable structures they have made.
  • Capacity, lead time, and cycle speed: in lead optimization a slow design-make-test cycle adds months across the dozens of iterations a real program needs. Pin down current queue, realistic delivery on a typical analog batch, FTE versus fee-for-service models, and what historically causes slippage. A great lab booked solid can be slower than a good lab with an open slot.
  • Scale-up and route track record: if you will need gram quantities for in vivo and tox, confirm they can scout a scalable route and deliver at scale without a painful handoff. A route that works at 10 mg and collapses at 5 g is a hidden cost.
  • Region and regulatory track record: location affects cost, time-zone overlap for daily SAR discussion, and shipping of controlled or hazardous materials. If this chemistry will eventually feed a GMP API campaign, ask whether the CRO or a sister site can carry the route into CMC so you are not re-developing it from scratch.
  • Data quality and reporting: you want clean SAR tables, straight reporting of compounds that failed or came back impure, full analytical files (not just a pass/fail), and registration-ready data you can load into your own system. Vague or selective reporting is a red flag.
  • IP and confidentiality: the molecules are the entire point. Confirm in writing that you own the compounds and inventions from the funded work, that platform or library-derived rights are not quietly retained, how compounds and data transfer to you, and how confidentiality is handled on a target you may not want disclosed.

Frequently asked questions

What is the difference between medicinal chemistry and synthetic chemistry?
They overlap heavily and most CROs sell them together. Medicinal chemistry is the design discipline: deciding which molecule to make next to improve potency, selectivity, solubility, or metabolic stability, reading the SAR, and balancing drug-like properties. Synthetic chemistry is the bench work: finding a route and actually making, purifying, and characterizing the molecule. A pure custom-synthesis engagement is synthesis-to-spec (you design, they make). A design-inclusive engagement adds the CRO's medicinal-chemistry judgment about what to make, which is usually where the real value sits in lead optimization.
How much does custom synthesis or a med chem CRO cost?
It depends on the difficulty of the chemistry, the scale, the purity and analytical package required, and whether you are buying per-compound or staffing an FTE team, so a single number would mislead. A simple known compound at milligram scale is inexpensive; a multi-step novel synthesis with chiral separation and gram-scale delivery is far more. For an active lead-optimization program, an FTE (full-time-equivalent) model with a fixed monthly rate per chemist is often more economical and predictable than pricing each analog. Define the scope, scale, and data deliverables, then compare quotes from several suppliers against the same specification.
What is an FTE model in medicinal chemistry outsourcing?
FTE stands for full-time equivalent. Instead of paying per compound, you pay a fixed monthly or annual rate for a dedicated chemist or team that works on your program continuously. It suits an active design-make-test program with steady demand, because the chemists accumulate context on your series and you are not renegotiating every batch. Fee-for-service (per-compound or per-project) suits finite, well-defined synthesis. Many sponsors run a hybrid: an FTE core for the optimization engine plus fee-for-service for occasional specialist syntheses.
Can AI replace a medicinal chemistry CRO?
Not on its own. Computational and AI tools (generative design, docking, free-energy perturbation, retrosynthesis prediction, ADMET models) are genuinely useful for proposing and ranking candidates and for cutting how many compounds you need to make. But molecules still have to be synthesized, purified, and tested in real assays, and an experienced medicinal chemist's judgment on synthesizability, scalability, and which series to pursue stays central. The strongest programs pair AI-driven design with a wet-lab chemistry partner rather than choosing one over the other.
Does medicinal and synthetic chemistry need to be done under GLP or GMP?
Generally no. Discovery medicinal and synthetic chemistry is research-grade work done under good scientific practice and good documentation, not GLP, which is a regulatory quality system for the safety studies that support an IND. GMP applies later still, to the API and drug product made for the clinic in the CMC and manufacturing stage. In discovery you want reproducibility and traceability: a defined analytical package per compound (LC-MS, NMR, HPLC purity), sound electronic-notebook practice, and characterized reference standards. Paying GMP prices for discovery analogs is wasted money.
Who owns the IP when you outsource medicinal chemistry?
In a well-structured engagement, the buyer owns the compounds, data, and inventions arising from the funded work. This is one of the most important terms to settle before any synthesis starts, because the molecules are the entire reason you are paying. Watch for suppliers with proprietary libraries or platforms who may retain rights to platform-derived structures, and confirm in writing how compounds, analytical records, and registration-ready data transfer to you. Treat ambiguous IP language as a red flag and resolve it in the contract, not after the first delivery.

Source Medicinal & Synthetic Chemistry with one contract

Compare transparent quotes from qualified Medicinal & Synthetic Chemistry CROs, then contract once. Free for buyers.

Compare quotes